



ImpediMed Limited
Suite 31C, 12-18 Tryon Rd
Lindfield NSW 2070
Australia

E: investorrelations@impedimed.com

W: impedimed.com

27 October 2026

Companies Announcements Office
Australian Securities Exchange

ImpediMed appoints cancer survivorship pioneer Dr. Nicole Stout to drive SOZO as standard of care

ImpediMed Limited (ASX: IPD), today announced that Nicole L. Stout, DPT, CLT-LANA, FAPTA, will join the Company as Chief Clinical Innovation Officer, effective 1 November, 2026. Dr. Stout will lead clinical strategy, research, medical affairs, and key opinion leader engagement, with a focus on accelerating the adoption of the SOZO® Digital Health Platform across care settings.

An internationally recognised authority in cancer rehabilitation and survivorship, Dr. Stout has spent more than 25 years helping oncology teams identify treatment-related complications early and intervene before they become disabling. She pairs that scientific record with years of experience putting new care models into practice inside health systems.

From evidence to clinical practice

Dr. Stout's pioneering research helped establish the evidence base for the Prospective Surveillance Model (PSM). The approach pairs pretreatment baseline assessments with risk-stratified interval monitoring, then refers patients to supportive care when changes appear, so care teams can address the physical and functional effects of cancer and its treatment throughout the care continuum.

Dr. Stout has designed and implemented surveillance pathways in health systems, resulting in shortened time to intervention for cancer treatment-related conditions and improved clinical operations and service-line performance. She has won support from executive and clinical leaders, then built the business and operational plans that turn new care models into lasting programs.

Most recently, as Senior Director of Survivorship and Wellness at the American Cancer Society, Dr. Stout led a national portfolio of programs and initiatives addressing supportive care needs across the cancer continuum. Her earlier clinical, research, and leadership experience includes roles at the West Virginia University Cancer Institute and the NIH Clinical Center. She has also led strategic initiatives involving the National Institutes of Health and the World Health Organization and has published more than 100 peer-reviewed and invited articles on survivorship care delivery.



Scaling prospective surveillance with SOZO

At ImpediMed, Dr. Stout will guide clinical strategies that help health systems accelerate the use of the SOZO Digital Health Platform across the oncology enterprise. The platform is already established in lymphedema assessment. The National Accreditation Program for Breast Centers (NAPBC) Optimal Resources for Breast Care 2027 standards also name bioimpedance spectroscopy (BIS) as a method that meets Standard 5.8, its new lymphedema assessment requirement. In August of 2026, ImpediMed received FDA 510(k) clearance for sarcopenia risk assessment, enabling care teams to use the same scan to monitor muscle loss. Together, they give health systems a foundation for surveillance programs that extend across cancer types and treatment settings.

“Nicole brings a rare combination of scientific leadership and a proven ability to translate innovation into clinical practice,” said Erik Anderson, Managing Director and Chief Executive Officer of ImpediMed. “She has built surveillance programs, navigated complex health system operations, influenced policy, and earned the trust of leaders across the oncology space for over 25 years. At the top of her career, Nicole is choosing to join this team to help define the next chapter of growth for this Company, bringing all of her experience to drive SOZO as a standard of care for cancer survivorship. We couldn’t be more excited to welcome Nicole to the team.”

“I am thrilled to be joining the team at this time. The evidence for early, proactive supportive care is compelling, but real impact depends on what health systems can consistently deliver,” said Dr. Stout. “My career has focused on making prospective surveillance practical by connecting objective assessment with clinical workflows, timely intervention, and measurable outcomes. I have been following the SOZO platform and BIS technology over many years, and now is the time to bring together this platform along with my expertise in clinical evidence and implementation to help oncology teams adopt sustainable models of care in cancer survivorship programs.”

Dr. Stout will join the Q1 FY27 Results Investor Webinar scheduled for 9.00am on Friday 30 October 2026 to introduce herself and discuss why she believes SOZO can become the standard of care for cancer survivorship.

Authorised for release by Erik Anderson, Managing Director and CEO.



About ImpediMed

Headquartered in Sydney, Australia with US and European operations, ImpediMed is a medical technology company that uses bioimpedance spectroscopy (BIS) technology to generate powerful data to maximise patient health. ImpediMed produces the SOZO® Digital Health Platform, which is FDA-cleared, CE-marked, and ARTG-listed for multiple indications, including lymphoedema, heart failure, and protein calorie malnutrition and sold in select markets globally.

In March 2024, the NCCN Clinical Practice Guidelines In Oncology (NCCN Guidelines®) for Survivorship continue to reference bioimpedance spectroscopy as the recommended objective tool to screen at-risk cancer patients for early signs of lymphoedema. With the SOZO Digital Health Platform and L-Dex®, ImpediMed is the only company to offer FDA-cleared technology that uses bioimpedance spectroscopy for the clinical assessment of lymphoedema. The connected digital health platform and large, attractive cancer-related lymphoedema market present an opportunity for continued strong growth through ImpediMed's SaaS subscription-based business.

For more information, visit www.impedimed.com.

Forward looking statements

This announcement contains or may contain forward-looking statements that are based on ImpediMed Limited (ImpediMed) management's beliefs, assumptions and expectations and on information currently available to management.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to our ability to expand sales and market acceptance in the US and Australia including our estimates of potential revenues, costs, profitability and financial performance; our ability to develop and commercialise new products including our ability to obtain reimbursement for our products; our expectations with respect to our clinical trials, including enrolment in or completion of our clinical trials and our associated regulatory submissions and approvals; our expectations with respect to the integrity or capabilities of our intellectual property position. Any forward-looking statements, including projections, guidance on future revenues, earnings and estimates, are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance.

While management has prepared this information based on its current knowledge and understanding and in good faith, there are risks and uncertainties involved which could cause actual results to differ from projections. You should not place undue reliance on forward-looking statements which speak only as of the date when made. Except as required by law, ImpediMed does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. ImpediMed may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements and no representation, warranty or assurance (express or implied) is given or made in relation to any forward-looking statement by any person (including ImpediMed Limited).